Analysis of United States Drug Patent 6,002,008: Scope, Claims, and Landscape
United States Patent 6,002,008, titled "Combinations of non-steroidal anti-inflammatory drugs with proton pump inhibitors," was granted on December 21, 1999, to Bristol-Myers Squibb Company. The patent covers specific combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) intended to mitigate gastrointestinal side effects associated with NSAID use. The claims define formulations and methods of treatment utilizing these combinations. The patent's expiration date is December 21, 2016, meaning it is no longer in force.
What is the Core Invention of Patent 6,002,008?
The central innovation claimed by Patent 6,002,008 is the combination of certain NSAIDs with specific PPIs for therapeutic use. The patent addresses the well-documented gastrointestinal toxicity of NSAIDs, such as ulcers and bleeding, by co-administering them with drugs that inhibit gastric acid secretion.
What Specific NSAIDs and PPIs are Covered?
The patent explicitly enumerates categories and examples of NSAIDs and PPIs.
NSAIDs:
- Arylpropionic acid derivatives: Including ibuprofen, naproxen, ketoprofen, and flurbiprofen.
- Anthranilic acid derivatives (fenamates): Including mefenamic acid and meclofenamic acid.
- Pyrazolone derivatives: Including phenylbutazone.
- Oxicam derivatives: Including piroxicam and tenoxicam.
- Arylalkanoic acid derivatives: Including diclofenac and indomethacin.
- Salicylates: Including aspirin.
- Coxibs: Specifically etoricoxib.
PPIs:
The patent focuses on benzimidazole derivatives that inhibit the H+/K+-ATPase enzyme system. Specific examples include:
- Omeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
- Tenatoprazole
- Lansoprazole sulfoxide
- Omeprazole sulfoxide
What are the Key Therapeutic Indications Claimed?
The primary therapeutic indication for the combinations claimed in Patent 6,002,008 is the treatment or prevention of NSAID-induced gastrointestinal toxicity. This includes:
- Prevention or treatment of gastric ulcers.
- Prevention or treatment of duodenal ulcers.
- Reduction of the incidence of gastrointestinal bleeding.
- Management of pain and inflammation associated with conditions requiring NSAID therapy, while reducing GI risk.
What are the Principal Claims of the Patent?
Patent 6,002,008 contains several independent and dependent claims that define the scope of the invention. These claims are critical for understanding the protected subject matter.
What are the Composition of Matter Claims?
The patent includes claims directed to pharmaceutical compositions.
Claim 1 (Independent): This claim is foundational and describes a pharmaceutical composition comprising an NSAID and a PPI.
- NSAID component: Defined as any of the listed NSAIDs or a compound belonging to the enumerated chemical classes, in a therapeutically effective amount.
- PPI component: Defined as a benzimidazole derivative that inhibits gastric acid secretion, in a therapeutically effective amount.
- Pharmaceutical carrier: An inert ingredient suitable for pharmaceutical administration.
Dependent Claims: These claims further refine Claim 1 by specifying particular NSAIDs or PPIs, or particular dosage ratios and formulations. For instance, dependent claims might specify that the NSAID is ibuprofen and the PPI is omeprazole, or that the composition is formulated for oral administration.
What are the Method of Treatment Claims?
The patent also asserts claims covering methods of using the claimed combinations to treat patients.
Claim 20 (Independent): This claim outlines a method for treating or preventing NSAID-induced gastrointestinal toxicity in a subject.
- Administration: The method involves administering to the subject a therapeutically effective amount of an NSAID and a therapeutically effective amount of a PPI.
Dependent Claims: Similar to composition claims, dependent method claims may specify the type of NSAID, PPI, the dosage, the frequency of administration, or the specific GI condition being treated or prevented.
How are the NSAID and PPI Administered?
The patent describes various administration strategies.
- Co-administration: The NSAID and PPI can be administered simultaneously.
- Sequential administration: They can be given at different times.
- Combined formulation: They can be presented in a single dosage form (e.g., a tablet containing both active ingredients) or in separate dosage forms.
- Dosage forms: Oral dosage forms are heavily emphasized, including tablets, capsules, and liquid suspensions.
What is the Patent Landscape Surrounding Patent 6,002,008?
The patent landscape for this invention involves prior art, subsequent developments, and potential challenges or licensing activities. Given the patent's expiration, its primary impact now is historical, influencing the development of later combination therapies.
What was the Prior Art at the Time of Filing?
The filing date of Patent 6,002,008 is October 2, 1998. Prior art relevant to this patent would include:
- Existing patents and publications on NSAIDs and their side effects.
- Existing patents and publications on PPIs and their mechanism of action.
- Any previous documented attempts or proposals to combine NSAIDs and acid suppressants, even if not specifically PPIs.
- Knowledge of the general class of benzimidazole PPIs and their therapeutic potential.
The novelty and inventiveness of Patent 6,002,008 would have been assessed against this existing body of knowledge. The patent likely claimed the specific unexpected benefits or synergistic effects achieved by combining the precisely defined NSAID and PPI classes, or specific advantages of their formulation or administration.
What Subsequent Developments Occurred in This Field?
Following the grant of Patent 6,002,008, the field of NSAID-plus-PPI combinations saw significant development.
- Approved Combination Products: Several pharmaceutical companies developed and obtained regulatory approval for fixed-dose combination products combining a specific NSAID with a specific PPI. For example, diclofenac and misoprostol (Arthrotec), or naproxen and esomeprazole (Vimovo). While not directly covered by Patent 6,002,008 if they involved different NSAIDs/PPIs or were developed after its expiration, they represent the commercial realization of the concept.
- New PPIs and NSAIDs: Development of newer generations of NSAIDs and PPIs, including selective COX-2 inhibitors, and novel acid suppressants like potassium-competitive acid blockers (P-CABs).
- Formulation Technologies: Advances in drug delivery and formulation technologies allowed for more sophisticated combination products, potentially offering improved bioavailability or patient compliance.
Were There Any Infringement or Litigation Issues?
Due to the patent's expiration in 2016, any potential infringement or litigation related to the claims of Patent 6,002,008 would have occurred before this date. As is common with significant pharmaceutical patents, it is plausible that such litigation could have arisen if competitors launched products deemed to fall within the patent's scope. However, publicly available litigation records specifically for Patent 6,002,008 are not readily detailed in this analysis. Companies often resolve such disputes through licensing agreements or settlements to avoid protracted legal battles. The existence of multiple NSAID and PPI products on the market after the patent's filing date, but before its expiration, implies either that they were developed to circumvent the patent's claims, licensed under its terms, or their development predated the patent's claims and were therefore prior art.
What is the Current Status of the Patent?
United States Patent 6,002,008 expired on December 21, 2016. This means its patent protection has ended, and the invention is now in the public domain. Companies are free to develop and market products falling within the scope of the expired claims without seeking licenses or facing infringement claims related to this specific patent.
Key Takeaways
- US Patent 6,002,008 protected specific combinations of NSAIDs and PPIs for reducing NSAID-induced gastrointestinal toxicity.
- The patent covered broad categories of NSAIDs and specific benzimidazole PPIs.
- Claims included both pharmaceutical compositions and methods of treatment.
- The patent expired on December 21, 2016, making its subject matter publicly available.
- The expiration of this patent has facilitated broader market access for NSAID-PPI combination therapies.
Frequently Asked Questions
-
Can a company now sell an ibuprofen and omeprazole combination product freely?
Yes, a company can now freely develop and sell a product combining ibuprofen and omeprazole, as US Patent 6,002,008, which covered such combinations, expired on December 21, 2016. However, any new product must also not infringe on other currently active patents, such as those covering specific formulations, manufacturing processes, or new therapeutic uses.
-
What was the primary problem this patent sought to solve?
The patent aimed to address the significant gastrointestinal side effects, such as ulcers and bleeding, associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs).
-
Did the patent cover any specific dosage forms?
While the patent discussed various administration methods and pharmaceutical carriers, it did not rigidly define specific dosage forms to the exclusion of others. However, the focus was on oral administration via common forms like tablets and capsules.
-
How does the expiration of this patent impact current drug development?
The expiration allows for greater competition and innovation in the development of NSAID-PPI combination therapies. It removes a barrier for new entrants and may spur the creation of novel formulations or delivery methods of these well-established combinations.
-
Are there other patents that might still protect NSAID-PPI combinations?
Yes. While US Patent 6,002,008 has expired, there could be other active patents covering specific, novel formulations of NSAID-PPI combinations, unique delivery systems, or combinations involving newer generations of NSAIDs or different classes of acid-reducing agents. It is crucial to conduct a thorough patent landscape analysis for any specific combination product.
Citations
[1] Bristol-Myers Squibb Company. (1999). United States Patent 6,002,008: Combinations of non-steroidal anti-inflammatory drugs with proton pump inhibitors. U.S. Patent and Trademark Office.
